Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden

Objective. There are only a few data on the prevalence of drug-induced liver injury associated with fatal outcome. The aim of this study was to determine the nature and number of suspected adverse drug-induced liver disease associated with fatalities and/or liver transplantation since reporting of adverse drug reactions (ADRs) started in Sweden.Material and methods. All reports of suspected hepatic ADRs with fatal outcome received by the Swedish Adverse Drug Reactions Advisory Committee (SADRAC) from 1966 to 2002 were reviewed and causality assessed.Results. The SADRAC received 151 reports of suspected ADRs with fatal outcome from liver injury; 48 cases were either unlikely or excluded. Of the remaining 103 cases, 13 (13%) were highly probable, 48 (47%) probable and 42 (41%) possible. The median age of the 103 patients was 64 years (47–77 interquartile range (IQR)) and 59 (57%) were males. The majority of cases were classified as hepatocellular (75%), with only 15% cholestatic and 10% mixed. Halothane, paracetamol, flucloxacillin, sulfamethoxazole/trimethoprim and diclofenac were the most common drugs associated with fatal outcome. Seventeen patients underwent liver transplantation, most commonly because of paracetamol and disulfiram toxicity.Conclusions. A wide range of suspected ADRs are associated with fatalities. Antibiotics and analgesics are associated with the greatest number of reports of deaths.

[1]  L. Holmberg,et al.  Fatal reactions to drugs. A 10-year material from the Swedish Adverse Drug Reaction Committee. , 2009, Acta medica Scandinavica.

[2]  O. Iversen,et al.  Infective hepatitis and toxic jaundice in a municipal hospital during a five-year period. Incidence and prognosis. , 2009, Acta medica Scandinavica.

[3]  R. Olsson,et al.  Drug‐induced hepatic injury in Sweden , 2003, Hepatology.

[4]  E. Björnsson,et al.  Severe Jaundice in Sweden in the New Millennium: Causes, Investigations, Treatment and Prognosis , 2003, Scandinavian journal of gastroenterology.

[5]  William M. Lee,et al.  Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States , 2002, Annals of Internal Medicine.

[6]  H. Isoniemi,et al.  Fulminant hepatic failure: Outcome after listing for highly urgent liver transplantation—12 years experience in the nordic countries , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[7]  X. Vidal,et al.  Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. , 2002, Journal of hepatology.

[8]  P. Hillon,et al.  Incidence of drug‐induced hepatic injuries: A French population‐based study , 2002, Hepatology.

[9]  M. Rawlins,et al.  Accuracy of hepatic adverse drug reaction reporting in one English health region , 1999, BMJ.

[10]  E. Grabsch,et al.  Postmarketing surveillance: strengths and limitations. The flucloxacillin–dicloxacillin story , 1999, The Medical journal of Australia.

[11]  R. Williams,et al.  Classification, Etiology, and Considerations of Outcome in Acute Liver Failure , 1996, Seminars in liver disease.

[12]  P. Pillans,et al.  Drug associated hepatic reactions in New Zealand: 21 years experience. , 1996, The New Zealand medical journal.

[13]  K. Ishak,et al.  Diclofenac‐associated hepatotoxicity: Analysis of 180 cases reported to the food and drug administration as adverse reactions , 1995, Hepatology.

[14]  J. Hoofnagle,et al.  Fulminant Hepatic Failure : Summary of a Workshop , 2017 .

[15]  G. Danan,et al.  Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. , 1993, Journal of clinical epidemiology.

[16]  J. McNeil,et al.  Risk factors for development of flucloxacillin associated jaundice. , 1993, BMJ.

[17]  H. Friis,et al.  Drug‐induced hepatic injury: an analysis of 1100 cases reported to The Danish Committee on Adverse Drug Reactions between 1978 and 1987 , 1992, Journal of internal medicine.

[18]  R. Hultcrantz,et al.  Liver damage from flucloxacillin, cloxacillin and dicloxacillin. , 1992, Journal of hepatology.

[19]  C. Bénichou Criteria of drug-induced liver disorders. Report of an international consensus meeting. , 1990, Journal of hepatology.

[20]  R Williams,et al.  Early indicators of prognosis in fulminant hepatic failure. , 1989, Gastroenterology.

[21]  B. Westerholm,et al.  Adverse Drug Reactions during treatment of urinary tract infections , 1977, European Journal of Clinical Pharmacology.

[22]  E. Forrest,et al.  Causes of obvious jaundice in South West Wales. Authors' reply , 2002 .

[23]  D. Crawford,et al.  Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic? , 1995, European journal of clinical pharmacology.

[24]  Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an international consensus meeting. , 1990, International journal of clinical pharmacology, therapy, and toxicology.

[25]  O. James Drugs and the ageing liver. , 1985, Journal of hepatology.

[26]  M. Black,et al.  Drug induced liver disease. , 1983, Postgraduate medical journal.

[27]  B. Bjerregaard,et al.  Causes and characteristics of 500 consecutive cases of jaundice. , 1981, Scandinavian journal of gastroenterology.